Children's study launched for AstraZeneca and Oxford vaccine

15 February 2021

The University of Oxford has launched a study to assess the responses in children and young adults to the ChAdOx1 nCoV-19 coronavirus vaccine that it has developed alongside AstraZeneca (LSE: AZN).

This trial will assess if children and young adults aged six to 17 years have a good immune response with ChAdOx1 nCoV-19, also known as COVID-19 Vaccine AstraZeneca.

The study follows previous trials of the vaccine, which have shown that it is safe, produces strong immune system responses and has high efficacy in all adults, albeit with results that are not as impressive as some of the other COVID-19 jabs. The lack of data so far in older patients has led certain European countries not to approve the vaccine in those groups.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK